A statistical evaluation of rules for biochemical failure after radiotherapy in men treated for prostate cancer.

[1]  James A Hanley,et al.  Detecting trends in noisy data series: application to biomarker series. , 2008, American journal of epidemiology.

[2]  James A Hanley,et al.  Hierarchical changepoint models for biochemical markers illustrated by tracking postradiotherapy prostate-specific antigen series in men with prostate cancer. , 2008, Annals of epidemiology.

[3]  G. Andriole.  13-Year Outcomes Following Treatment for Clinically Localized Prostate Cancer in a Population Based Cohort , 2007 .

[4]  D. Kuban,et al.  Biochemical and clinical significance of the posttreatment prostate‐specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone , 2006, Cancer.

[5]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[6]  A. Hanlon,et al.  Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer. , 2005, International journal of radiation oncology, biology, physics.

[7]  D. Kuban,et al.  Defining recurrence after radiation for prostate cancer. , 2005, The Journal of urology.

[8]  D. Kuban,et al.  Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis. , 2005, The Journal of urology.

[9]  D. Kuban,et al.  Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. , 2003, International journal of radiation oncology, biology, physics.

[10]  A. Zietman,et al.  Influence of follow-up bias on PSA failure after external beam radiotherapy for localized prostate cancer: results from a 10-year cohort analysis. , 2003, International journal of radiation oncology, biology, physics.

[11]  A. Hanlon,et al.  Modifying the American Society for Therapeutic Radiology and Oncology definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3-dimensional conformal radiation therapy alone. , 2003, The Journal of urology.

[12]  Colin B Begg,et al.  Variation of serum prostate-specific antigen levels: an evaluation of year-to-year fluctuations. , 2003, JAMA.

[13]  A. Hanlon,et al.  Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. , 2002, International journal of radiation oncology, biology, physics.

[14]  F. Critz.  A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. , 2002, The Journal of urology.

[15]  Robert C. Frazier,et al.  Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy , 1999, Cancer.

[16]  D. Kuban,et al.  Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. , 1999, JAMA.

[17]  James D. Cox,et al.  Consensus statement: Guidelines for PSA following radiation therapy , 1997 .

[18]  E. Metter,et al.  Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. , 1992, JAMA.